Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 6/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | XDH | P47989 | 2/20 | 0.38 |
| ▸ | MAT2A | P31153 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753360 | 0.92 | TDP2 (0.46) | TDP2MCHR1MAPTXDHMAT2A | |
| SCHEMBL1754753 | 0.92 | MAPT (0.48) | TDP2MCHR1MAPTXDH | |
| SCHEMBL1689328 | 0.89 | TDP2 (0.42) | TDP2XDHMAT2A | |
| SCHEMBL4172203 | 0.87 | XDH (0.39) | TDP2MCHR1MAPTXDHMAT2A | |
| SCHEMBL4169089 | 0.86 | XDH (0.44) | MCHR1MAPTXDH | |
| SCHEMBL4165895 | 0.86 | XDH (0.38) | TDP2MCHR1MAPTXDHMAT2A | |
| SCHEMBL1689079 | 0.85 | MAPT (0.49) | MCHR1MAPTXDH | |
| SCHEMBL1689130 | 0.85 | MAPT (0.49) | MCHR1MAPTXDH | |
| SCHEMBL13651679 | 0.85 | MCHR1 (0.39) | MCHR1MAPTXDH | |
| SCHEMBL15694340 | 0.84 | MAPT (0.41) | MCHR1MAPTXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722691-B2 | Azolopyrimidines as inhibitors of cannabinoid 1 activity | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| US-8722691-B2 | Azolopyrimidines as inhibitors of cannabinoid 1 activity | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| US-8722691-B2 | Azolopyrimidines as inhibitors of cannabinoid 1 activity | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| EP-1999132-B1 | AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY | IRM LLC (BM) | 2012-07-18 | — | — | EP | disclosed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | CNR1, CNR2, ITPR2 | TDP2 3658/4885MCHR1 1596/4885MAPT 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.